Souhaitez-vous accéder aux communiqués récents ?

Financiële resultaten van de eerste negen maanden: Totale omzet gestegen met €17,8 M tot €65,0 M Operationeel verlies met €14,8 M gedaald tot €48,5 M Kaspositie van €938,8 M op 30 september...

Financial results of the first nine months: Group revenues increased by €17.8 M to €65.0 M Operating loss reduced by €14.8 M to €48.5 M End of third quarter cash €938.8 M Progress in...

                                                                                           Negen posters en vier presentaties demonstreren klinische voortgang op weg naar een drievoudige...

                                                               Nine posters and four oral presentations reflect clinical progress toward triple combination therapy Mechelen, Belgium; 27 October...

    Mechelen, België; 12 oktober 2016, 22.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) heeft een kennisgeving van belangrijke deelneming ontvangen van Fidelity Management &...

    Mechelen, Belgium; 12 October 2016, 22.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Fidelity Management & Research (FMR) LLC. ...

You are cordially invited to attend an informal gathering for the buy and sell side with Galapagos during NACFC 2016 in Orlando, Florida: Date/time: Thursday Oct 27th, 7 - 8pm, drinks and snacks...

You are cordially invited to attend an informal gathering for the buy and sell side with Galapagos during NACFC 2016 in Orlando, Florida: Date/time: Thursday Oct 27th, 7 - 8pm, drinks and snacks...

Lopende Fase 1 studie in gezonde vrijwilligers gaat over in onderzoek bij patiënten met atopische dermatitis Gunstige veiligheidsresultaten in gezonde vrijwilligers met enkelvoudige oplopende...

Ongoing Phase 1 study in healthy volunteers now advanced to investigate MOR106 in patients with atopic dermatitis Favorable safety results shown in healthy volunteers receiving single ascending...